UK Markets close in 6 hrs 34 mins
  • FTSE 100

    7,037.95
    -40.47 (-0.57%)
     
  • FTSE 250

    22,946.85
    -103.61 (-0.45%)
     
  • AIM

    1,242.98
    -4.29 (-0.34%)
     
  • GBP/EUR

    1.1742
    +0.0005 (+0.04%)
     
  • GBP/USD

    1.3975
    +0.0018 (+0.1258%)
     
  • BTC-GBP

    27,671.81
    -1,052.44 (-3.66%)
     
  • CMC Crypto 200

    921.20
    -9.16 (-0.98%)
     
  • S&P 500

    4,419.15
    +18.51 (+0.42%)
     
  • DOW

    35,084.53
    +153.60 (+0.44%)
     
  • CRUDE OIL

    73.49
    -0.13 (-0.18%)
     
  • GOLD FUTURES

    1,833.20
    -2.60 (-0.14%)
     
  • NIKKEI 225

    27,283.59
    -498.83 (-1.80%)
     
  • HANG SENG

    25,961.03
    -354.29 (-1.35%)
     
  • DAX

    15,524.34
    -116.13 (-0.74%)
     
  • CAC 40

    6,640.63
    +6.86 (+0.10%)
     

Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting

·2-min read

LONDON, June 25, 2021 (GLOBE NEWSWIRE) -- At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.

The results of the proxy voting will be available shortly on the Company's website, https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting.

The Company also confirms that it has re-activated its strategic plan to redomicile to Bermuda; shareholders will receive further information in due course.

The person who arranged for the release of this announcement was Keeren Shah, Chief Financial Officer.

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohns Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.

For further enquiries:
United Kingdom:

Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder

+44 (0)20 7495 2379


United States:

Investors:
Dave Gentry, CEO
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
or
407-491-4498
dave@redchip.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting